The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.
CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.
Michael McKee is accused of making the journey from Illinois to Ohio and then shooting the two victims in their home on Dec. 30. He was arrested after surveillance footage showed his car at the scene before and after the murders.
The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.
The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.
Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.
